Abrocinitib was slightly more effective than dupilumab in treating atopic dermatitis, both in White patients and in patients with skin of color.

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the launch of AdvanceAD-Tx™, a gene expression profile (GEP) test ...

What exactly is severe AD? AD is the most common type of eczema. When this eczema becomes severe, a person has patches of skin that are red, swollen, and unbearably itchy. The patches of AD can weep ...

EBGLYSS (lebrikizumab-lbkz) sustained similar levels of skin clearance when administered as a single injection of 250 mg once every eight weeks (Q8W) compared with once every four weeks (Q4W), ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting an observational cohort study titled ‘Treating ...

Nektar Therapeutics NKTR reported a loss of $1.87 per share for the third quarter of 2025, narrower than the Zacks Consensus ...

Eli Lilly has reported that its interleukin-13 (IL-13) inhibitor Ebglyss (lebrikizumab-lbkz) showed sustained skin clearance ...

The immune drugmaker is the second biotech, along with MapLight Therapeutics, to recently use a workaround in U.S. securities ...

Children with atopic dermatitis (AD), commonly known as eczema, may experience fewer infections and allergic complications if ...

COVID-19 vaccination may help children with eczema fight infections and allergies, offering protection that goes far beyond ...

Children with atopic dermatitis (AD), commonly known as eczema, may experience fewer infections and allergic complications if they receive the COVID-19 vaccine, according to new research being ...